SOURCES SOUGHT
A -- Independent Consultants for Scientific Merit Review Board for
- Notice Date
- 1/29/2016
- Notice Type
- Sources Sought
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of the Army, Army Contracting Command, ACC - APG (W911QY) Natick (SPS), BLDG 1 KANSAS ST, Natick, Massachusetts, 01760-5011, United States
- ZIP Code
- 01760-5011
- Solicitation Number
- W911QY-16-S-0002
- Archive Date
- 3/2/2016
- Point of Contact
- JENNIFER S. BASSETT, Phone: 301-619-8401
- E-Mail Address
-
JENNIFER.S.BASSETT.CIV@MAIL.MIL
(JENNIFER.S.BASSETT.CIV@MAIL.MIL)
- Small Business Set-Aside
- N/A
- Description
- The purpose of this Request for Information (RFI) is to identify qualified independent consultants interested in supporting membership for our Independent Scientific Merit Review Board for clinical studies. This is a Request for Information (RFI) for planning purposes only, as defined in FAR 15.201(e). This is not a solicitation or request for competitive proposals. Responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. It is not to be construed as a commitment by the Government nor will the Government pay for the information solicited. No solicitation document exists or is guaranteed to be issued as a result of this RFI. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. The Government will not reimburse respondents for preparation of the response. OBJECTIVES: Responding individuals must meet the following requirements and demonstrate capabilities & experience in a submitted curriculum vitae (CV). Dynport Vaccine Company LLC (DVC), a CSRA Company is seeking consultants meeting the following criteria: 1. Individuals with the following education, training and experience: A. M.D. physician, with clinical and research experience in the design of clinical trials, and board-certification in internal medicine, specializing in infectious diseases preferred or specializing in allergy and immunology; B. Ph.D. or M.D. research scientist with experience in one or more of the following areas: microbiology, virology, bacteriology, vaccinology, immunology or other therapeutic areas of note; C. Biostatistician with a graduate degree, preferably Ph.D., and experience in the design of Phase 1 to Phase 3 clinical trials (Safety, PK/PD, and efficacy studies) 2. Individuals must be US Citizens or legal permanent residents (green card) 3. Individuals have research experience or equivalent scientific merit 4. Willing to sign confidentiality disclosures, financial disclosures, and comply with International Traffic and Arms Regulations (ITAR) SUBMISSION INSTRUCTIONS: Respondents to this notice must provide, as part of their response, a capability statement that includes, clear and convincing documentation of their capability of providing the requirement as specified in this notice. The information submitted must be must be in an outline format that addresses each of the elements of the project requirement. The response is limited to ten (10) pages. The 10-page limit does not include the cover page, executive summary, or references, if provided. All written responses must be received within Fifteen (15) Calendar Days of issuance of this RFI. Submissions should: (1) Use Microsoft Word or Adobe Portable Document Format (PDF); (2) Be sent to the POCs identified below (email is preferred); (3) Be complete, sufficiently detailed, and organized in a manner that tracks to the information requested in this RFI; (4) Include a single company point of contact with name, title, address, telephone numbers, and e-mail address (es); and (5) Not exceed 10 single-sided pages in total (not including the cover page, executive summary, or references). Other media types (i.e., CD, printed technical information) that meet the submission criteria above will be accepted. Material that is advertisement only in nature is not desired. Please address responses to this notice to: DVC requests that you provide a response directly to Linda Howell at Linda.Howell@csra.com indicating your interest in pursuing further discussions. Should DVC elect to pursue discussions, a Non-Disclosure Agreement will be executed. Should you have interest, please include in your response a recent curriculum vitae and the following Business information as applicable: a. DUNS number or CAGE Code b. Company Name c. Company Address d. Company Points of Contact (both technical and administrative/business), including names, titles, addresses, telephone and fax numbers and email addresses. e. Type of Company (i.e. small business, 8(a), woman owned, veteran owned, etc). Please designate a company point of contact (telephone, address, and email). All questions regarding this RFI must be in writing or emailed. No telephone inquiries will be accepted. The North American Industry Classification System (NAICS) Code for this notice is 541711 "Research and Development in Biotechnology" with a size standard of 500 employees. Responders must identify their company's business size (based on the NAICS size standard), business status (i.e. small business, disadvantaged, HUBzone, woman owned, service disabled veteran owned). Please ensure that your registration in the System for Award Management (SAM) is up to date prior to submission of your response. Further information and registration information may be found at the following website: https://www.sam.gov/portal/public/SAM/
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/notices/b9aa3d9e6be2066b1606de994ef994d7)
- Record
- SN04005208-W 20160131/160129234548-b9aa3d9e6be2066b1606de994ef994d7 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |